The next big thing for global Pharma - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

The next big thing for global Pharma

Oct 15, 2009

Emerging economies have been garnering a lot of interest of late as far as investments are concerned. Not only are the developed economies mired in a recession but the prospects also do not look too enthusing in the near future atleast. In stark contrast, emerging economies led by China and India are expected to post strong growth rates, a phenomenon which will be witnessed in the global pharmaceutical industry as well. Thus, in this article, we shall take a look at what is driving the growth of branded generics in these emerging markets. Domestic pharma's branded focus

Indian pharma companies were at the forefront in capitalising on the branded generics opportunity. As a result, their exports strategy not only revolved around selling generic medicines in the developed nations of the US and Europe but also in the semi or less regulated markets of Asia, Africa, Russia and the CIS. The latter especially were lucrative because generic medicines there can be branded and hence pushed through doctors. This could not be done in the US and Europe, which are heavily regulated. Here, generic medicines cannot be branded unless companies can show that their versions are more effective due to superior technology or a superior delivery mechanism. However, in the semi or less regulated markets, generics can be branded just like they are in India. But since they are not subject to price control as in India, the revenue and profit potential is that much higher.

Domestic companies such as Ranbaxy, Dr.Reddy's, Sun Pharma, Glenmark, Lupin, Cadila and the like are looking to enhance their presence in these regions especially when the US and European generics markets in recent times have been marred by intense competition and price erosion.

Global innovators jumping the bandwagon

Another breed of pharma companies have also realized the potential of branded generics and are looking to grab a slice of the branded generics pie. We are talking about the global innovators such as Pfizer Inc., GSK Plc, Sanofi-Aventis and the like, which previously focused on developing patented drugs. There are various reasons for wanting to dabble in generics as well. First is that their own research pipelines are drying up with not much to show for the amount of money invested in R&D. Secondly, many of their blockbusters are going off patent which would mean a huge drop in sales and profits. Thirdly, governments across the world are looking to cut healthcare costs by encouraging the use of generics. Little wonder than that Big Pharma which hitherto was averse to generics, is now finding itself joining hands with Indian generic players to foray into emerging markets. Case in point would be Pfizer Inc.'s partnership with Aurobindo Pharma and GSK Pharma's alliance with Dr.Reddy's amongst others.

Going forward...

We believe that branded generics will play an important role in driving the growth of the global pharmaceutical market. This is not to say that the US generics market will not witness growth as there are many patent expiries on the anvil. But because margins in the US are low, the emerging markets will form an important business for domestic pharma companies. As far as the global pharma markets are concerned, while the US pharma market is projected to register a decline of 1%-2% in 2009, the top five European markets (France Germany, the UK, Italy and Spain) are forecast to grow at 3%-4% in 2009.

This means that emerging markets (including India and China) will be the next frontier and these markets, which logged in a healthy growth of 12% in 2008, are expected to grow collectively at 13% to 16% up to 2013. Infact, the seven emerging markets (China, Brazil, India, South Korea, Mexico, Turkey and Russia) are expected to contribute 40% to the global market growth from 2009 to 2013 (Source: Dr.Reddy's annual report). Thus, akin to other industries, the pharma industry in the emerging markets hold huge potential and Indian pharma companies which are firmly entrenched in these markets stand to benefit immensely from the same.

Equitymaster requests your view! Post a comment on "The next big thing for global Pharma". Click here!

1 Responses to "The next big thing for global Pharma"


Oct 28, 2009

I have nt at received Midcapselect recommendatio for this wednsday 28/10/09

Equitymaster requests your view! Post a comment on "The next big thing for global Pharma". Click here!

More Views on News

STRIDES PHARMA SCIENCE Share Price Up by 5%; BSE HEALTHCARE Index Down 0.2% (Market Updates)

Sep 29, 2020 | Updated on Sep 29, 2020

STRIDES PHARMA SCIENCE share price is trading up by 5% and its current market price is Rs 747. The BSE HEALTHCARE is down by 0.2%. The top gainers in the BSE HEALTHCARE Index are STRIDES PHARMA SCIENCE (up 5.3%) and BLISS GVS PHARMA (up 5.1%). The top losers are FDC LTD. (down 0.1%) and DIVIS LABORATORIES (down 0.2%).

GRANULES INDIA at All Time High; BSE HEALTHCARE Index Up 0.5% (Market Updates)

Sep 29, 2020 | Updated on Sep 29, 2020

GRANULES INDIA share price has hit an all time high at Rs 407 (up 1.6%). The BSE HEALTHCARE Index is up by 0.5%. Among the top gainers in the BSE HEALTHCARE Index today are GRANULES INDIA (up 1.6%) and ABBOTT INDIA (up 0.4%). The top losers include ASTRAZENECA PHARMA (down 0.1%) and LUPIN (down 0.1%).

FDC LTD. at All Time High; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Sep 29, 2020 | Updated on Sep 29, 2020

FDC LTD. share price has hit an all time high at Rs 378 (up 1.6%). The BSE HEALTHCARE Index is up by 0.2%. Among the top gainers in the BSE HEALTHCARE Index today are FDC LTD. (up 1.6%) and ABBOTT INDIA (up 0.2%). The top losers include ALEMBIC PHARMA and GLENMARK PHARMA (down 0.2%).

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 29, 2020 03:01 PM